An Open Label, Non-Randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects.

Trial Profile

An Open Label, Non-Randomized Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 After Oral Administration to Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2010

At a glance

  • Drugs AZD 2066 (Primary)
  • Indications Gastro-oesophageal reflux; Neuropathic pain
  • Focus Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2010 Actual end date changed from Jul 2008 to Jun 2008 as reported by ClinicalTrials.gov.
    • 18 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top